Partner with Hedera Dx
Empowering multicenter collaboration and local research
With the goal of fostering collaborations across centers and investigators, generating valuable clinical insights, and delivering high-quality Real-World Evidence to advance precision oncology, researchers, healthcare professionals and patients will gain a deeper understanding of how specific genetic characteristics of a tumor may influence its behavior and response to treatment. The resulting knowledge will be accessible to investigators for their own research and will help further guide personalized and targeted approaches to cancer care, leading to more effective treatment strategies tailored to individual patients.
Revolutionizing global decentralized tumor profiling data collection for better personalized care
Hedera Frame is a platform for globally unique precision oncology data, gathering longitudinal clinicogenomics data in real-world settings from both cancer patients and clinical investigators. The data is patient-centric with active participation from patients reporting Patient-Reported Outcomes (PROs) and Patient-Reported Experience Measures (PREMs). This transformative initiative aims to place patients at the center of their own care and foster a collaborative relationship between healthcare providers, patient groups and individuals, leading to better care and meaningful advancements in healthcare practices.
EMPATHY NSCLC
ClinicalTrials.gov Identifier: NCT07096258
EMPATHY NSCLC (European Molecular PlasmA profiling liquid-biopsy program in THE NSCLC patients), our flagship registry, is the first prospective, multi-country, multi-center clinico-genomic study investigating the Real-World utility of the European, decentralized NGS-based molecular profiling and monitoring approach, enabling prospective Real-World assessment of current NGS/ctDNA-based practices across Europe's decentralized healthcare landscape.
In addition, it represents the first component of a larger, pan-cancer longitudinal clinicogenomics initiative, aimed at collecting real-life testing patterns with liquid biopsies, to ultimately unleash the potential of this highly promising technology and develop the next generation of breakthrough personalized therapies.
Through the myHedera app, patients actively participate in their care by contributing Patient-Reported Outcomes (PROs) and Patient-Reported Experience Measures (PREMs), adding a critical real-world dimension to our clinico-genomic datasets.
We partner with biopharma and take oncology R&D further by leveraging decentralized tumor profiling, RWE and patient centric approaches
Our prospective clinico-genomic registry platform captures longitudinal, trial-grade molecular and clinical outcomes data at the point of care. We support the full value chain, from deploying NGS/ctDNA testing for comprehensive molecular profiling and monitoring through to RWE-ready datasets that inform clinical drug development, companion diagnostic development, and market access.
Built on an established network of leading oncology centers, our platform supports nested substudies, biomarker validation, and real-world evidence generation, ultimately contributing to more therapy options for more patients.
Sequencing Services
Our core sequencing service offering is NGS-based tumor profiling and monitoring through both tissue and liquid biopsy, enabling identification of actionable molecular alterations, treatment response tracking, and early detection of resistance or progression. For translational research programs, we provide sequencing solutions that support clinical trials, companion diagnostic development, and biomarker-driven patient stratification, with the ability to link molecular results to longitudinal clinical and patient-reported outcomes through our registry infrastructure.
